About Implex Corporation
Implex is a manufacturer of orthopedic implant devices. Implex holds the exclusive worldwide rights to Hedrocel, a promising orthopedic implant material being designed into a number of implant products. Other institutional investors include Innocal, Oracle Strategic Partners, and Argosy Partners. Implex was sold to Zimmer Holdings (NYSE:ZMH) in 2004.
Missing: Implex Corporation's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Implex Corporation's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Implex Corporation News
Jan 14, 2013
ScripsAmerica Enters Into Investment Banking Consulting Agreement With Implex Corporation January 14, 2013 12:00 ET | Source: ScripsAmerica, Inc. NEW CASTLE, Del., Jan. 14, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (OTCBB: SCRC ), a leading supplier of prescription, OTC and nutraceutical drugs, today announced that the Company has entered into an Investment Banking Consulting Agreement with Implex Corporation (Implex), headquartered in Jensen Beach, FL. The consulting agreement has an initial term of six months whereby Implex will provide ScripsAmerica with corporate, business and investment banking services, including the analysis and the rendering of advice on the Company's current corporate and financial structures as well as its need for capitalization. In addition, Implex will assist ScripsAmerica in any negotiations and structuring of the sale and/or purchase of businesses, mergers, strategic alliances or distribution agreements as well as advise on the sale of any securities in the public market. "2013 is going to be a very positive and pivotal year for ScripsAmerica as we plan to launch our RapiMed line of children's pain reliever, finalize the acquisition of our pharmaceutical distributor, explore opportunities to continue our organic growth and increase shareholder value. For these reasons, we have engaged Implex Corporation to provide ScripsAmerica with a full range of investment banking services such as financial analysis and advice as well as introductions to the appropriate players in the investment community that can help ensure our success during this anticipated period of significant growth," stated Bob Schneiderman, CEO of ScripsAmerica. About ScripsAmerica, Inc. ScripsAmerica, Inc. delivers pharmaceutical products to a wide range of end users across the health care industry, including physicians' offices, retail pharmacies, long-term care sites, hospitals, and Government and home care agencies through the largest pharmaceutical distributor in North America, McKesson Corporation. Current therapeutic categories serviced by the Company include pain, arthritis, prenatal, urinary, and hormonal replacement drugs. Other customers of ScripsAmerica include Cardinal Health, Curtis Pharmaceuticals, MedVet and the United States Veterans Administration. For more information please visit: www.ScripsAmerica.com . Safe Harbor Statement This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 888-959-7095
Implex Corporation Frequently Asked Questions (FAQ)
Where is Implex Corporation's headquarters?
Implex Corporation's headquarters is located at 48 Horsehill Road, Cedar Knolls.
What is Implex Corporation's latest funding round?
Implex Corporation's latest funding round is Acquired.
How much did Implex Corporation raise?
Implex Corporation raised a total of $30.36M.
Who are the investors of Implex Corporation?
Investors of Implex Corporation include Zimmer Biomet and MVP Capital Partners.
Who are Implex Corporation's competitors?
Competitors of Implex Corporation include Tepha, Noraker, Neoss, OrthAlign, AcuFocus and 13 more.
Compare Implex Corporation to Competitors
Freedom Innovations is a high technology provider of premium prosthetic devices, a growing segment of the non-invasive orthopedic market. It deals with making prosthetic devices with latest technological developments and customization for lower limb amputations. The branded carbon fiber foot products lead the industry in reputation and growth rate. The company's first microprocessor-controlled product, the Pli' MPC Knee, was introduced in May 2007, serving as an entry into the SMART technology arena.What aims to make the company and the products is the high customization in the prosthetic devices market ranging from different limbs for swimmers to bikers to soldiers and so on.In February 2012, Health Evolution Partners acquired a majority stake in Freedom Innovations. The valuation of Freedom Innovations was undisclosed. Other terms of the deal were not released.
Dental Implant Technologies (DIT) is a San Antonio based dental technology company providing an end to end suite of integrated implant based restorative services and products for dental patients requiring the replacement of most or all of their teeth. In the United States alone this market includes 30M individuals or a served addressable market of $96B including $26B for DIT's products and services.
BioControl - New generation of active implantable devices affecting the behavior of muscles and nerves of the autonomic nervous system. The company sold its urology business for $90M to American Medical Systems.
IMI Intelligent Medical Implants GmbH, the developer of the Learning Retinal Implant System. This homepage is also suitable for blind and visually impaired users.
Autocam Medical manufactures high-precision components, instruments, implants and handpieces for a variety of medical applications. Some of the company's products include implants, instruments, handpieces, and components.
Neoss is developing dental implant technology.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.